Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib plus docetaxel and cisplatin versus docetaxel and cisplatin in EGFR-mutant T790M-negative advanced NSCLC after EGFR-TKI failure
ChiCTR1800018222Phase 4Not yet recruiting
- Sponsor
- The First Affiliated Hospital, Anhui Medical University
- Start
- Oct 2018
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of anlotinib, docetaxel and cisplatin in non-small cell lung cancer (NSCLC) (2 arms), sponsored by The First Affiliated Hospital, Anhui Medical University. Primary endpoint: progression-free survival. Planned start Oct 2018; status: not yet recruiting.
02
Drugs
anlotinibdocetaxelcisplatin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR1800018222.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800018222.